[{"address1": "200 Inner Belt Road", "address2": "Suite 400", "city": "Somerville", "state": "MA", "zip": "02143", "country": "United States", "phone": "617 229 6499", "website": "https://www.finchtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.", "fullTimeEmployees": 1, "companyOfficers": [{"maxAge": 1, "name": "Mr. Matthew P. Blischak J.D.", "title": "Chief Executive Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Lance  Thibault CPA", "age": 57, "title": "Chief Financial Officer", "yearBorn": 1966, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James S. Sigler MBA", "age": 62, "title": "Executive Vice President of CMC", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 2.29, "open": 2.25, "dayLow": 2.1, "dayHigh": 2.3099, "regularMarketPreviousClose": 2.29, "regularMarketOpen": 2.25, "regularMarketDayLow": 2.1, "regularMarketDayHigh": 2.3099, "beta": 0.46, "forwardPE": -0.10879067, "volume": 41613, "regularMarketVolume": 41613, "averageVolume": 45148, "averageVolume10days": 182270, "averageDailyVolume10Day": 182270, "marketCap": 3596902, "fiftyTwoWeekLow": 1.86, "fiftyTwoWeekHigh": 16.74, "priceToSalesTrailing12Months": 33.615906, "fiftyDayAverage": 2.52444, "twoHundredDayAverage": 4.312655, "currency": "USD", "enterpriseValue": 8598909, "floatShares": 792862, "sharesOutstanding": 1605760, "sharesShort": 10600, "sharesShortPriorMonth": 11631, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0066000004, "heldPercentInsiders": 0.53481, "heldPercentInstitutions": 0.15017, "shortRatio": 0.87, "shortPercentOfFloat": 0.0117, "impliedSharesOutstanding": 1605760, "bookValue": 14.252, "priceToBook": 0.15717092, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -74754000, "trailingEps": -46.59, "forwardEps": -20.59, "lastSplitFactor": "1:30", "lastSplitDate": 1686528000, "enterpriseToRevenue": 80.364, "enterpriseToEbitda": -0.265, "52WeekChange": -0.8147229, "SandP52WeekChange": 0.21080327, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "FNCH", "underlyingSymbol": "FNCH", "shortName": "Finch Therapeutics Group, Inc.", "longName": "Finch Therapeutics Group, Inc.", "firstTradeDateEpochUtc": 1616160600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b8e86349-7dce-3756-a76c-43df24d3f738", "messageBoardId": "finmb_320858778", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.24, "targetHighPrice": 90.0, "targetLowPrice": 90.0, "targetMeanPrice": 90.0, "targetMedianPrice": 90.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 25124000, "totalCashPerShare": 15.646, "ebitda": -32482000, "totalDebt": 30126000, "quickRatio": 6.152, "currentRatio": 6.329, "totalRevenue": 107000, "debtToEquity": 131.635, "revenuePerShare": 0.067, "returnOnAssets": -0.19469, "returnOnEquity": -1.26064, "freeCashflow": -23909250, "operatingCashflow": -31505000, "revenueGrowth": -1.0, "operatingMargins": -317.7757, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-26"}]